Partnership coordination
The Long-acting Partnerships Strategy was initiated to prioritise partnerships that accelerate achievement of global targets to reduce morbidity and mortality from malaria, hepatitis C virus, tuberculosis, HIV and coinfections / comorbidities. The project incorporates activities that support knowledge sharing to accelerate equitable availability and access to long-acting products in low- and middle- income countries, and on ensuring sustainability and reduction of the environmental footprint associated with research, manufacturing, distribution and delivery.
Project overview
The Long-acting Partnership Strategy brings together four core activities aimed at accelerating the development and equitable uptake of long-acting therapeutics, especially in low- and middle- income countries (LMICs):
- A long-acting workshop series
- A long-acting annual conference
- A long-acting projects dashboard.
The workshop series will convene researchers, clinicians, implementers, regulators, manufacturers, funders, and patient advocates to surface evidence and gaps, and share best practice in research and development, manufacturing, delivery, and pharmacovigilance.
The annual conference will align evidence, policy, and market actions so innovation translates into equitable health impact, particularly in LMICs.
Finally, the dashboard will give researchers, regulators, patient advocates, procurement agencies, and programme managers a curated global view of who is doing what, where, and on what timelines to support coordinated decision-making.
CELT Global Health's objectives
- Facilitate the exchange of updates and information on the relevant aspects of the long-acting landscape
- Facilitate development of collaborative working relationships with stakeholder groups
- Platform and engaging with LMIC stakeholders
- Promote visibility of long-acting LMIC orientated projects throughout academia and industry
- Provide reporting and a means of sharing metrics to help promote progress and learning.
LA-GLOBAL
We're pleased to launch LA-GLOBAL, a brand new conference curated and hosted by CELT Global Health.
LA-GLOBAL's mission is to accelerate the translation of long-acting science into equitable health outcomes, particularly for communities in low- and middle-income countries where the need is greatest and access has historically lagged furthest behind.
Registration and abstract submission are now open (abstract deadline 08.07.26, early bird tickets deadline 22.07.26). Find out more on our LA-GLOBAL conference page.
Sponsorship packages can also be found on LA-GLOBAL's sponsorship page.
Keynotes
Each LA-GLOBAL theme has a keynote speaker and we're pleased to announce them:
- Advances in long-acting manufacturing - Professor Ryan Donnelly from Queen's University Belfast
- Frontiers in long-acting drug delivery - Professor René Holm from the University of Southern Denmark
- Maternal and paediatric health - Professor Elaine Abrams from Columbia University
- Biological performance of long-acting therapeutics - Dr Alison Cave from Medicines and Healthcare products Regulatory Agency (MHRA)
- Preclinical pharmacology and pharmacometrics - Professor Pieter Annaert from KU Leuven.
LA-LINK
We host a seminar and workshop series designed to bring together researchers, developers, policymakers, funders, and implementers working across the rapidly evolving field of long-acting therapeutics.
Long-acting medicines and technologies are transforming prevention and treatment for a range of conditions that disproportionately affect people in low- and middle- income countries (LMICs). As the field advances, so does the need for accessible medicines, and LA-LINK aims to be a cross-stakeholder learning space where expertise can be shared, challenges identified, and new collaborations connected.
What is LA-LINK?
LA-LINK (Long-acting Learning, Innovation, Networks and Knowledge) is a recurring online seminar and workshop series hosted by CELT Global Health. Each session will feature experts from across academia, industry, global health organisations, and regulatory bodies, sharing insights on the science, strategy, and implementation of long-acting technologies.
Why Now?
The long-acting field is expanding, with new technologies, regulatory pathways, and platforms are emerging, but knowledge often sits in silos and bottlenecks can sometimes be discovered late in a project/product lifecycle. By creating a regular convening point, LA-LINK will help:
- Highlight cutting-edge research, technology and innovation
- Share lessons learned across disease areas and geographies
- Strengthen connections between global partners and reveal new potential opportunities for partnership and pilot programmes
- Support evidence-based decision-making for long-acting products in development and deployment
What to expect
Each webinar will feature:
- Focused expert talks or panels
- Space for questions and answers and community discussion
- Session summaries and materials shared afterward
Topics will include long-acting formulations, regulatory considerations, modelling, PK, clinical trial design manufacturing, PPI, access, emerging technologies, public-private partnerships, operational research, and more.
We hope that LA-LINK will become a resource of information and will lead to practical takeaways for developers, policymakers, and programme leads
Upcoming session(s)
We'll update here and on our Events page with the details of the next workshop once it's ready for you.
Previous sessions
Pharmacokinetic modelling - January 2026
The first LA-LINK session was ‘Application of pharmacokinetic modelling and simulation for long-acting medicines’.
The workshop involved four different talks:
- Dr Francis Ojara Williams (Gulu University - Uganda) - LAI Using Modelling and Simulation Based Approaches
- Professor Robert Bies (University at Buffalo - USA) - Population Pharmacokinetics of Long Acting Cabotegravir Injection
- Harshal Hattyangdi (CELT Global Health) - TEORELER 2.0 Demonstration - A Free Web-based Physiologically-Based Pharmacokinetic (PBPK) Modelling Application
- Dr Catia Marzolini (University of Lausanne and University of Basel - Switzerland) - Application of PBPK modeling to simulate LA cabotegravir / rilpivirine pharmacokinetics in special populations and drug-drug interactions
A recording of the full session can be seen in the video below:
Access - May 2026
This workshop was titled 'Putting community voices at the centre of access to long-acting medicines'. It shifted the focus to the people at the heart of access - the communities who will receive, deliver, and advocate for long-acting medicines.
Through a moderated panel and open discussion, we heard directly from community leaders, advocates, and access experts on the real-world barriers to equitable access, the role of trust and information in preparing communities for new treatments, and what meaningful community involvement looks like from clinical trial design through to delivery.
Panelists for this access focused workshop were:
- Osei Boateng - Ghana - Founder of the OKB Hope Foundation
- Shatyam Issur - India, Mauritius - Public health and Fundraising Consultant , Member of LONGEVITY's Long-acting Technologies Community Advisory Board (LATCAB)
- Ketho Angami - India - Founder of ARK Foundation and member of the TB Community Advisory Board and LATCAB
- Jacque Wambui - Kenya - HIV-positive activist and Global CAB Facilitator at the Afrocab Treatment Access Partnership, member of the LATCAB
- Belinda Ameterra, South Africa — Member of the LATCAB & Boland Research Community Advisory Board.
A recording of the full session can be seen in the video below:
Awarding body
The Partnership Coordination project is sponsored by global health agency Unitaid.
